CRISPR Therapeutics AG Outperforms Market, Earnings Expectations Ahead

CRISPR Therapeutics AG (CRSP) closed at $47.09, a +1.42% gain from the previous session, outpacing the S&P 500's 0.54% gain. The upcoming earnings release is expected to show an EPS of -$1.15, a 27.22% rise from the same quarter last year, and revenue of $7.32 million, a 741.03% increase. The Zacks Rank system, which assesses estimated changes and delivers an operational rating system, currently ranks CRSP at #3 (Hold). The Medical - Biomedical and Genetics industry is ranked 146, in the bottom 41% of all industries.